| Literature DB >> 19620246 |
Karim Abid1, Bertrand Rochat, Paul-Gerhard Lassahn, Reto Stöcklin, Sophie Michalet, Noureddine Brakch, Jean-Francois Aubert, Bilgin Vatansever, Patricia Tella, Ingrid De Meester, Eric Grouzmann.
Abstract
There is little information on how neuropeptide Y (NPY) proteolysis by peptidases occurs in serum, in part because reliable techniques are lacking to distinguish different NPY immunoreactive forms and also because the factors affecting the expression of these enzymes have been poorly studied. In the present study, LC-MS/MS was used to identify and quantify NPY fragments resulting from peptidolytic cleavage of NPY(1-36) upon incubation with human serum. Kinetic studies indicated that NPY(1-36) is rapidly cleaved in serum into 3 main fragments with the following order of efficacy: NPY(3-36) >> NPY(3-35) > NPY(2-36). Trace amounts of additional NPY forms were identified by accurate mass spectrometry. Specific inhibitors of dipeptidyl peptidase IV, kallikrein, and aminopeptidase P prevented the production of NPY(3-36), NPY(3-35), and NPY(2-36), respectively. Plasma kallikrein at physiological concentrations converted NPY(3-36) into NPY(3-35). Receptor binding assays revealed that NPY(3-35) is unable to bind to NPY Y1, Y2, and Y5 receptors; thus NPY(3-35) may represent the major metabolic clearance product of the Y2/Y5 agonist, NPY(3-36).Entities:
Mesh:
Substances:
Year: 2009 PMID: 19620246 PMCID: PMC2757175 DOI: 10.1074/jbc.M109.035253
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157